Ascendis Pharma AS Total Liabilities
Ascendis Pharma AS total liabilities. Based on the latest financial reports, Ascendis Pharma AS (A71) has total liabilities worth €1.52 Billion EUR (≈ $1.77 Billion USD) as of March 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. See defensive interval ratio of Ascendis Pharma AS to measure how many days the company can operate on defensive assets alone.
Total Liabilities of Ascendis Pharma AS (2016–2025)
Total liabilities of Ascendis Pharma AS from 2016 to 2025. This chart illustrates how Ascendis Pharma AS's total liabilities have evolved over time, based on quarterly financial data. Check asset resilience ratio of Ascendis Pharma AS to evaluate the company's liquid asset resilience ratio.
Ascendis Pharma AS Competitors by Total Liabilities
The table below lists competitors of Ascendis Pharma AS ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Penumbra Inc
NYSE:PEN
|
USA | $443.96 Million |
|
Lifco AB (publ)
ST:LIFCO-B
|
Sweden | Skr23.20 Billion |
|
China Tungsten and Hightech Materials Co Ltd
SHE:000657
|
China | CN¥18.73 Billion |
|
Hanmi Semicon
KO:042700
|
Korea | ₩123.00 Billion |
|
KUAISHOU TECHNOLOGY CL.B
F:5Y0
|
Germany | €84.82 Billion |
|
Taiwan Union Technology
TWO:6274
|
Taiwan | NT$22.79 Billion |
|
Zhejiang Satellite Petrochemical Co Ltd
SHE:002648
|
China | CN¥39.17 Billion |
|
BWX Technologies Inc
NYSE:BWXT
|
USA | $3.09 Billion |
Liability Composition Analysis (2016–2025)
This chart breaks down Ascendis Pharma AS's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see A71 total assets.
Liquidity & Leverage Metrics
Ascendis Pharma AS Total Liabilities Ratios Explained
Ascendis Pharma AS total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 1.00 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 3.11 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.76 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Ascendis Pharma AS's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Ascendis Pharma AS (2016–2025)
The table below shows the annual total liabilities of Ascendis Pharma AS from 2016 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | €1.47 Billion ≈ $1.71 Billion |
+14.02% |
| 2024-12-31 | €1.29 Billion ≈ $1.50 Billion |
+32.32% |
| 2023-12-31 | €971.28 Million ≈ $1.14 Billion |
+17.53% |
| 2022-12-31 | €826.39 Million ≈ $966.14 Million |
+310.56% |
| 2021-12-31 | €201.29 Million ≈ $235.32 Million |
+42.67% |
| 2020-12-31 | €141.08 Million ≈ $164.94 Million |
+77.20% |
| 2019-12-31 | €79.62 Million ≈ $93.08 Million |
+104.58% |
| 2018-12-31 | €38.92 Million ≈ $45.50 Million |
+63.74% |
| 2017-12-31 | €23.77 Million ≈ $27.79 Million |
+76.61% |
| 2016-12-31 | €13.46 Million ≈ $15.73 Million |
-- |
About Ascendis Pharma AS
Ascendis Pharma A/S, operates as a biopharmaceutical company that focuses on developing TransCon-based therapies for unmet medical needs in Europe, the United States, and internationally. The company offers SKYTROFA for treating pediatric patients with growth hormone deficiency; and YORVIPATH, a once-daily subcutaneous injection for the treatment of adults with chronic hypoparathyroidism. It is a… Read more